Published in Gene Therapy Weekly, September 1st, 2005
ZymoGenetics has granted the underwriters in the offering an option to purchase 975,000 shares of common stock to cover over-allotments. Merrill Lynch & Co. will act as the lead manager for the offering. Pacific Growth Equities, LLC, Bear, Stearns & Co. Inc. and Piper Jaffray & Co. will act as co-managers.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.